Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cetuximab, a chimeric mouse-human IgG1 monoclonal antibody against the epidermal growth factor receptor, is approved for use in colorectal cancer and squamous-cell carcinoma of the head and neck. A high prevalence of hypersensitivity reactions to cetuximab has been reported in some areas of the United States. METHODS: We analyzed serum samples from four groups of subjects for IgE antibodies against cetuximab: pretreatment samples from 76 case subjects who had been treated with cetuximab at multiple centers, predominantly in Tennessee, Arkansas, and North Carolina; samples from 72 control subjects in Tennessee; samples from 49 control subjects with cancer in northern California; and samples from 341 female control subjects in Boston. RESULTS: Among 76 cetuximab-treated subjects, 25 had a hypersensitivity reaction to the drug. IgE antibodies against cetuximab were found in pretreatment samples from 17 of these subjects; only 1 of 51 subjects who did not have a hypersensitivity reaction had such antibodies (P<0.001). IgE antibodies against cetuximab were found in 15 of 72 samples (20.8%) from control subjects in Tennessee, in 3 of 49 samples (6.1%) from northern California, and in 2 of 341 samples (0.6%) from Boston. The IgE antibodies were shown to be specific for an oligosaccharide, galactose-alpha-1,3-galactose, which is present on the Fab portion of the cetuximab heavy chain. CONCLUSIONS: In most subjects who had a hypersensitivity reaction to cetuximab, IgE antibodies against cetuximab were present in serum before therapy. The antibodies were specific for galactose-alpha-1,3-galactose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Humans also lack the ability to produce the Galα1–3Galβ1–4GlcNAc–R epitope, which is common in murine cells, and this has been shown to induce anaphylaxis [8,33].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Murine cells can also produce α-gal and Neu5Gc at considerably higher levels than hamster cells, increasing the risks of immunogenicity (Tangvoranuntakul et al., 2003;Chung et al., 2008;Macher and Galili, 2008;Padler-Karavani et al., 2008;Ghaderi et al., 2012).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Chung et al., 2008
Experimental — accuracy not yet measuredIn the citing paper
“However, anti-α-Gal IgE antibodies can cause allergic reactions, such as anaphylaxis, against cetuximab, a therapeutic monoclonal antibody targeting epidermal growth factor receptor (EGFR)”
From ABO blood group antigens and differential glycan expression: Perspective on the evolution of common human enzyme deficiencies (2023) · cites this paper as Chung et al., 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Chung, K. Y., Shia, J., Kemeny, N. E., Shah, M., Schwartz, G. K., Tse, A., Hamilton, A., Pan, D., Schrag, D., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.037 · Cited by 1,081
(1945) · Harvard University Press eBooks · doi:10.4159/harvard.9780674184220 · Cited by 1,078
The diagnosis and management of anaphylaxis: An updated practice parameter
LIEBERMAN, P., KEMP, S., OPPENHEIMER, J., LANG, D., BERNSTEIN, I., NICKLAS, R., ANDERSON, J., BERNSTEIN, D., BERNSTEIN, J., & FINK, J. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.01.010 · Cited by 667
Symposium on the Definition and Management of Anaphylaxis: Summary report
Sampson, H. A., Muñoz-Furlong, A., Bock, S. A., Schmitt, C., Bass, R., Chowdhury, B. A., Decker, W. W., Furlong, T. J., Galli, S. J., Golden, D. B., et al. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.01.009 · Cited by 641
The incidence and management of infusion reactions to infliximab: a large center experience
Cheifetz, A. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(03)00231-4 · Cited by 491
The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation
Holgate, S., Casale, T., Wenzel, S., Bousquet, J., Deniz, Y., & Reisner, C. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.11.053 · Cited by 466
Research works printed but not linked: 1
- Carolina; association with atopic history. J Clin Oncol 2007;25:3644-8.
Cited by
Items 301–400 of 1,002
Anti-Drug Antibody Response to Therapeutic Antibodies and Potential Mitigation Strategies
Howard, E. L., Goens, M. M., Susta, L., Patel, A. R., & Wootton, S. K. (2025) · Biomedicines · doi:10.3390/biomedicines13020299 · Cited by 70
Prater, B. D., Connelly, H. M., Qin, Q., & Cockrill, S. L. (2008) · Analytical Biochemistry · doi:10.1016/j.ab.2008.10.023 · Cited by 70
Peeters, M., Price, T. J., & Laethem, J. V. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0167 · Cited by 73
Alpha‐gal is a possible target of IgE‐mediated reactivity to antivenom
Fischer, J., Eberlein, B., Hilger, C., Eyer, F., Eyerich, S., Ollert, M., & Biedermann, T. (2017) · Allergy · doi:10.1111/all.13073 · Cited by 64
In Vitro Diagnosis of Immediate Drug Hypersensitivity Anno 2017: Potentials and Limitations
Decuyper, I. I., Mangodt, E. A., Gasse, A. L. V., Claesen, K., Uyttebroek, A. P., Faber, M. A., Sabato, V., Bridts, C. H., Mertens, C. H., Hagendorens, M. M., et al. (2017) · Drugs in R&D · doi:10.1007/s40268-017-0176-x · Cited by 67
Teixeira, A. A. R., Erasmus, M. F., D’Angelo, S., Naranjo, L. A., Ferrara, F., Leal‐Lopes, C., Durrant, O., Galmiche, C., Morelli, A., Scott-Tucker, A., et al. (2021) · mAbs · doi:10.1080/19420862.2021.1980942 · Cited by 73
Kersh, G. J., Salzer, J., Jones, E. S., Binder, A. M., Armstrong, P. A., Choudhary, S. K., Commins, G. K., Amelio, C. L., Kato, C. Y., Singleton, J., et al. (2023) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2022.11.021 · Cited by 61
Mammalian Cell Line Developments in Speed and Efficiency
Estes, S. D., & Melville, M. W. (2013) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2013_260 · Cited by 79
Glycosylation profiles of therapeutic antibody pharmaceuticals
Wacker, C., Berger, C. N., Girard, P., & Meier, R. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.06.010 · Cited by 69
Developability assessment as an early de-risking tool for biopharmaceutical development
Zurdo, J. (2013) · Pharmaceutical Bioprocessing · doi:10.4155/pbp.13.3 · Cited by 75
Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering
Yu, X., Marshall, M. J. E., Cragg, M. S., & Crispin, M. (2017) · BioDrugs · doi:10.1007/s40259-017-0223-8 · Cited by 71
Apostolovic, D., Rodrigues, R., Thomas, P., Starkhammar, M., Hamsten, C., & van Hage, M. (2018) · Allergy · doi:10.1111/all.13400 · Cited by 61
The Meat of the Matter: Understanding and Managing Alpha-Gal Syndrome
Macdougall, J. D., Thomas, K. O., & Iweala, O. I. (2022) · ImmunoTargets and Therapy · doi:10.2147/itt.s276872 · Cited by 64
Factor VIII and von Willebrand factor – too sweet for their own good
Lenting, P. J., Pegon, J. N., Christophe, O. D., & Denis, C. V. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2010.02320.x · Cited by 64
Reversed-phase liquid-chromatographic mass spectrometric N-glycan analysis of biopharmaceuticals
Higel, F., Demelbauer, U. M., Seidl, A., Frieß, W., & Sörgel, F. (2013) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-012-6690-3 · Cited by 70
Mezzano, V., Junior, P. F. G.-B., Picard, M., Caiado, J., & Castells, M. (2013) · BioDrugs · doi:10.1007/s40259-013-0066-x · Cited by 68
Xue, L., & Rup, B. J. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9497-z · Cited by 64
Reusch, D., Haberger, M., Kailich, T., Heidenreich, A.-K., Kampe, M., Bulau, P., & Wuhrer, M. (2014) · mAbs · doi:10.4161/mabs.26712 · Cited by 61
Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy
Wheatley, L. M., Plaut, M., Schwaninger, J. M., Banerji, A., Castells, M., Finkelman, F. D., Gleich, G. J., Guttman‐Yassky, E., Mallal, S. A., Naisbitt, D. J., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.05.027 · Cited by 68
Self-citationChandrasekhar, J. L., Cox, K. M., Loo, W. M., Qiao, H., Tung, K. S., & Erickson, L. D. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801156 · Cited by 60
Delayed Anaphylaxis Involving IgE to Galactose-alpha-1,3-galactose
Platts‐Mills, T. A. E., Schuyler, A. J., Hoyt, A., & Commins, S. P. (2015) · Current Allergy and Asthma Reports · doi:10.1007/s11882-015-0512-6 · Cited by 68
Self-citationMicrobial strategies for copper pollution remediation: Mechanistic insights and recent advances
Alkhanjaf, A. A. M., Sharma, S., Sharma, M., Kumar, R., Arora, N. K., Kumar, B., Umar, A., Baskoutas, S., & Mukherjee, T. K. (2024) · Environmental Pollution · doi:10.1016/j.envpol.2024.123588 · Cited by 66
Drug allergens and food—the cetuximab and galactose-α-1,3-galactose story
Berg, E. A., Platts‐Mills, T. A. E., & Commins, S. P. (2013) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2013.11.014 · Cited by 75
Self-citationMateos-Hernández, L., Villar, M., Moral, A., Rodríguez, C. G., Arias, T. A., de la Osa, V., Brito, F. F., Fernández de Mera, I. G., Alberdi, P., Ruiz-Fons, F., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15243 · Cited by 62
Jimenez del Val, I., Fan, Y., & Weilguny, D. (2016) · Biotechnology Journal · doi:10.1002/biot.201400663 · Cited by 62
Janin-Bussat, M.-C., Tonini, L., Huillet, C., Colas, O., Klinguer, C., Corvaïa, N., & Beck, A. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-327-5_7 · Cited by 62
European Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London, UK
Reichert, J. M., Beck, A., & Iyer, H. V. (2009) · mAbs · doi:10.4161/mabs.1.5.9630 · Cited by 61
High-throughput work flow for IgG Fc-glycosylation analysis of biotechnological samples
Reusch, D., Haberger, M., Selman, M. H. J., Bulau, P., Deelder, A. M., Wuhrer, M., & Engler, N. (2012) · Analytical Biochemistry · doi:10.1016/j.ab.2012.09.032 · Cited by 63
Anaphylactic Reactions to Oligosaccharides in Red Meat: a Syndrome in Evolution
Saleh, H., Embry, S., Nauli, A. M., Atyia, S., & Krishnaswamy, G. A. (2012) · Clinical and Molecular Allergy · doi:10.1186/1476-7961-10-5 · Cited by 66
de Haan, N., Reiding, K. R., Krištić, J., Ederveen, A. L. H., Lauc, G., & Wuhrer, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00608 · Cited by 68
Kverneland, A. H., Enevold, C., Donia, M., Bastholt, L., Svane, I. M., & Nielsen, C. H. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1424674 · Cited by 60
Drug rechanneling: A novel paradigm for cancer treatment
Kaushik, I., Ramachandran, S., Prasad, S., & Srivastava, S. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.03.011 · Cited by 65
The Possible Role of Anti-Neu5Gc as an Obstacle in Xenotransplantation
Tector, A. J., Mosser, M., Tector, M., & Bach, J.-M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00622 · Cited by 60
Cetuximab in the treatment of patients with colorectal cancer
Garrett, C. R., & Eng, C. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.582464 · Cited by 66
The epidemiology of food allergy in adults
Warren, C., Nimmagadda, S. R., Gupta, R., & Levin, M. (2023) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2022.11.026 · Cited by 57
Narasimhan, C. N., Mach, H., & Shameem, M. (2012) · Therapeutic Delivery · doi:10.4155/tde.12.68 · Cited by 63
Anaphylaxis to Chemotherapy and Monoclonal Antibodies
Castells, M. (2015) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2015.01.011 · Cited by 60
High prevalence of sIgE to Galactose‐α‐1,3‐galactose in rural pre‐Alps area: a cross‐sectional study
Villalta, D., Pantarotto, L., Re, M., Conte, M., Sjölander, S., Borres, M. P., & Martelli, P. R. (2015) · Clinical & Experimental Allergy · doi:10.1111/cea.12655 · Cited by 62
Angiotensin-converting Enzyme Inhibitor and Other Drug-associated Angioedema
Stone, C. A., & Brown, N. J. (2017) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2017.04.006 · Cited by 65
Gülşen, A., Wedi, B., & Jappe, U. (2020) · Allergo Journal International · doi:10.1007/s40629-020-00126-6 · Cited by 62
Mariotte, D., Dupont, B., Gervais, R., Galais, M., Laroche, D., Tranchant, A., Comby, E., Bouhier‐Leporrier, K., Reimund, J., & Mauff, B. L. (2011) · mAbs · doi:10.4161/mabs.3.4.16293 · Cited by 62
Antibody glycosylation: impact on antibody drug characteristics and quality control
Wang, Z., Zhu, J., & Lu, H. (2020) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-020-10368-7 · Cited by 67
IgE immunotherapy: A novel concept with promise for the treatment of cancer
Josephs, D. H., Spicer, J. F., Karagiannis, P., Gould, H. J., & Karagiannis, S. N. (2014) · mAbs · doi:10.4161/mabs.27029 · Cited by 58
A PSGL-1 glycomimetic reduces thrombus burden without affecting hemostasis
Wong, D. J., Park, D., Park, S. J., Haller, C. A., Chen, J., Dai, E., Liu, L., Mandhapati, A. R., Eradi, P., Dhakal, B., et al. (2021) · Blood · doi:10.1182/blood.2020009428 · Cited by 58
Reuel, N. F., Mu, B., Zhang, J., Hinckley, A. C., & Strano, M. S. (2012) · Chemical Society Reviews · doi:10.1039/c2cs35142k · Cited by 61
Immunogenicity of pembrolizumab in patients with advanced tumors
van Vugt, M. J. H., Stone, J. A., De Greef, “. H. J. M. M., Snyder, E. S., Lipka, L., Turner, D. C., Chain, A., Lala, M., Li, M., Robey, S. H., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0663-4 · Cited by 57
Mast cells and IgE in defense against lethality of venoms: Possible “benefit” of allergy
Galli, S. J., Metz, M., Starkl, P., Marichal, T., & Tsai, M. (2020) · Allergo Journal International · doi:10.1007/s40629-020-00118-6 · Cited by 57
Kumpel, B. M. (2008) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2008.03735.x · Cited by 57
Immediate‐type hypersensitivity drug reactions
Stone, S. F., Phillips, E. J., Wiese, M. D., Heddle, R. J., & Brown, S. G. A. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12297 · Cited by 57
Immunogenicity Assays for Antibody–Drug Conjugates: Case Study with Ado-Trastuzumab Emtansine
Carrasco‐Triguero, M., Yi, J., Dere, R. C., Qiu, Z. J., Lei, C., Li, Y., Mahood, C., Wang, B., Leipold, D. D., Poon, K. A., et al. (2013) · Bioanalysis · doi:10.4155/bio.13.64 · Cited by 58
Biosimilars entering the clinic without animal studies: A paradigm shift in the European Union
van Aerts, L., Smet, K. D., Reichmann, G., van der Laan, J. W., & Schneider, C. K. (2014) · mAbs · doi:10.4161/mabs.29848 · Cited by 62
Ten Years of Progress in Head and Neck Cancers
Baxi, S. S., Fury, M. G., Ganly, I., Rao, S. D., & Pfister, D. G. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0084 · Cited by 56
Laminin γ-1 and collagen α-1 (VI) chain are galactose-α-1,3-galactose-bound allergens in beef
Takahashi, H., Chinuki, Y., Tanaka, A., & Morita, E. (2014) · Allergy · doi:10.1111/all.12302 · Cited by 56
Discovery and Investigation of O -Xylosylation in Engineered Proteins Containing a (GGGGS) n Linker
Wen, D., Foley, S. F., Hronowski, X. L., Gu, S., & Meier, W. (2013) · Analytical Chemistry · doi:10.1021/ac400596g · Cited by 55
Naruse, T., Yanamoto, S., Matsushita, Y., Sakamoto, Y., Morishita, K., Ohba, S., Shiraishi, T., Yamada, S., Asahina, I., & Umeda, M. (2016) · Molecular and Clinical Oncology · doi:10.3892/mco.2016.928 · Cited by 59
Product Quality Considerations for Mammalian Cell Culture Process Development and Manufacturing
Gramer, M. J. (2013) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2013_214 · Cited by 62
Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters
Barbosa, M. D. F. S. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.01.011 · Cited by 58
Targeted treatments in colorectal cancer: state of the art and future perspectives
Arnold, D., & Seufferlein, T. (2010) · Gut · doi:10.1136/gut.2009.196006 · Cited by 67
Zeng, L., Beggs, R. R., Cooper, T. S., Weaver, A. N., & Yang, E. S.-H. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0352 · Cited by 54
Current and Future Strategies for the Diagnosis and Treatment of the Alpha-Gal Syndrome (AGS)
Vaz-Rodrigues, R., Mazuecos, L., & de la Fuente, J. (2022) · Journal of Asthma and Allergy · doi:10.2147/jaa.s265660 · Cited by 53
Alsenaidy, M. A., Jain, N. K., Kim, J. H., Middaugh, C. R., & Volkin, D. B. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00039 · Cited by 56
Pathogenesis of drug allergy – current concepts and recent insights
Schnyder, B., & Brockow, K. (2015) · Clinical & Experimental Allergy · doi:10.1111/cea.12591 · Cited by 59
The importance of early identification of infusion-related reactions to monoclonal antibodies
Cáceres, M. C., Guerrero-Martín, J., Pérez-Civantos, D. V., Palomo‐López, P., Delgado-Mingorance, J. I., & Durán‐Gómez, N. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s204909 · Cited by 53
Adverse drug reactions to biologics
Scherer, K., Spoerl, D., & Bircher, A. J. (2010) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2010.07339.x · Cited by 53
The α-Gal epitope - the cause of a global allergic disease
Perusko, M., Grundström, J., Eldh, M., Hamsten, C., Apostolovic, D., & van Hage, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1335911 · Cited by 52
McGuire, M. J., Gray, B. P., Li, S., Cupka, D., Byers, L. A., Wu, L., Rezaie, S., Liu, Y.-H., Pattisapu, N., Issac, J., et al. (2014) · Scientific Reports · doi:10.1038/srep04480 · Cited by 55
Glyco-engineering for biopharmaceutical production in moss bioreactors
Decker, E. L., Parsons, J., & Reski, R. (2014) · Frontiers in Plant Science · doi:10.3389/fpls.2014.00346 · Cited by 58
Doherty, M., Bones, J., McLoughlin, N., Telford, J. E., Harmon, B. J., DeFelippis, M. R., & Rudd, P. M. (2013) · Analytical Biochemistry · doi:10.1016/j.ab.2013.07.005 · Cited by 52
Michel, S., Scherer, K., Heijnen, I., & Bircher, A. J. (2013) · Allergy · doi:10.1111/all.12344 · Cited by 56
Protein Glycosylation and Its Impact on Biotechnology
Berger, M., Kaup, M., & Blanchard, V. (2011) · Springer eBooks · doi:10.1007/10_2011_101 · Cited by 57
Emerging Technologies and Generic Assays for the Detection of Anti-Drug Antibodies
Partridge, M. A., Purushothama, S., Elango, C., & Lu, Y. (2016) · Journal of Immunology Research · doi:10.1155/2016/6262383 · Cited by 53
Jappe, U., Minge, S., Kreft, B., Ludwig, A., Przybilla, B., Walker, A., Varga, R., Seidel, P., Biedermann, T., Anemüller, W., et al. (2018) · Allergy · doi:10.1111/all.13238 · Cited by 51
Self-citationOn enzymatic remodeling of IgG glycosylation; unique tools with broad applications
Sjögren, J., Lood, R., & Naegeli, A. (2019) · Glycobiology · doi:10.1093/glycob/cwz085 · Cited by 54
Drug Hypersensitivity Reactions
Dykewicz, M. S., & Lam, J. K. (2019) · Medical Clinics of North America · doi:10.1016/j.mcna.2019.09.003 · Cited by 58
Basophils from Cancer Patients Respond to Immune Stimuli and Predict Clinical Outcome
Bax, H. J., Chauhan, J., Stavraka, C., Khiabany, A., Nakamura, M., Pellizzari, G., Ilieva, K. M., Lombardi, S., Gould, H. J., Corrigan, C. J., et al. (2020) · Cells · doi:10.3390/cells9071631 · Cited by 52
Siena, S., Glynne‐Jones, R., Adenis, A., Thaler, J., Preusser, P., Aguilar, E. A., Aapro, M., Loos, A. H., Esser, R., & Wilke, H. (2010) · Cancer · doi:10.1002/cncr.24945 · Cited by 52
Peeters, M., BALFOUR, J., & Arnold, D. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03717.x · Cited by 57
Wen, Y., & Jawa, V. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.12.003 · Cited by 53
AGA Clinical Practice Update on Alpha-Gal Syndrome for the GI Clinician: Commentary
McGill, S., Hashash, J. G., & Platts‐Mills, T. A. E. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.12.035 · Cited by 53
Self-citationAnaphylaxis to cow's milk formula containing short-chain galacto-oligosaccharide
Chiang, W. C., Huang, C., Llanora, G., Gerez, I. F. A., Goh, S. H., Shek, L. P., Nauta, A. J., Doorn, W. A. V., BINDELS, J. G., Ulfman, L. H., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.08.048 · Cited by 55
The red meat allergy syndrome in Sweden
Apostolovic, D., Tran, T. A. T., Starkhammar, M., Sánchez-Vidaurre, S., Hamsten, C., & Van Hage, M. (2016) · Allergo Journal International · doi:10.1007/s40629-016-0098-0 · Cited by 48
Biological considerations of plasma-derived and recombinant factor VIII immunogenicity
Lai, J. D., Hough, C. A., Tarrant, J., & Lillicrap, D. (2017) · Blood · doi:10.1182/blood-2016-11-750885 · Cited by 51
Clinical and laboratory features of patients diagnosed with alpha‐gal syndrome—2010–2019
Binder, A. M., Cherry‐Brown, D., Biggerstaff, B. J., Jones, E. S., Amelio, C. L., Beard, C. B., Petersen, L. R., Kersh, G. J., Commins, S. P., & Armstrong, P. A. (2022) · Allergy · doi:10.1111/all.15539 · Cited by 53
The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
Mehra, R. (2010) · Biologics · doi:10.2147/btt.s3050 · Cited by 63
Hypersensitivity Reactions to Biologic Agents
Vultaggio, A., & Castells, M. (2014) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2014.04.008 · Cited by 50
Uyttebroek, A. P., Sabato, V., Bridts, C. H., Clerck, L. S. D., & Ebo, D. G. (2014) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2014.04.014 · Cited by 54
Kollmann, D., Nagl, B., Ebner, C., Emminger, W., Wöhrl, S., Kitzmüller, C., Vrtala, S., Mangold, A., Ankersmit, H.-J., & Bohle, B. (2017) · Allergy · doi:10.1111/all.12948 · Cited by 50
Dunkman, W. J., Rycek, W., & Manning, M. W. (2019) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000003460 · Cited by 45
Safety of Intravenous Heparin for Cardiac Surgery in Patients With Alpha-Gal Syndrome
Hawkins, R. B., Wilson, J. M., Mehaffey, J. H., Platts-Mills, T. A. E., & Ailawadi, G. (2021) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2020.07.050 · Cited by 49
Self-citationVernon, S. T., Kott, K. A., Hansen, T., Finemore, M., Baumgart, K. W., Bhindi, R., Yang, J. Y. H., HANSEN, P. S., Nicholls, S. J., Celermajer, D. S., et al. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316878 · Cited by 53
Zhang, X., Liu, H., He, J., Ou, C., Donahue, T. C., Muthana, M. M., Su, L., & Wang, L. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.1c00751 · Cited by 51
Wu, Y., Wen, H., Bernstein, Z. J., Hainline, K. M., Blakney, T. S., Congdon, K. L., Snyder, D. J., Sampson, J. H., Sanchez-Perez, L. A., & Collier, J. H. (2022) · Science Advances · doi:10.1126/sciadv.abm7833 · Cited by 51
Emerging trends and therapeutic applications of monoclonal antibodies
Ramaiah, M. J., Nalluri, H. P., Reddy, P. N., Sainath, S. B., Kumar, N. S. S., Sai Kiran, G. V. S. D., Dhiman, R., Chamarthy, S., Komaragiri, R. R., Manyam, R. R., et al. (2024) · Gene · doi:10.1016/j.gene.2024.148607 · Cited by 51
Using GlycoDelete to produce proteins lacking plant-specific N-glycan modification in seeds
Piron, R., Santens, F., Paepe, A. D., Depicker, A., & Callewaert, N. (2015) · Nature Biotechnology · doi:10.1038/nbt.3359 · Cited by 49
Toyama, A., Nakagawa, H., Matsuda, K., Sato, T., Nakamura, Y., & Ueda, K. (2012) · Analytical Chemistry · doi:10.1021/ac3023372 · Cited by 50
Reuel, N. F., Grassbaugh, B. R., Kruss, S., Mundy, J. Z., Opel, C. F., Ogunniyi, A. O., Egodage, K. L., Wahl, R., Helk, B., Zhang, J., et al. (2013) · ACS Nano · doi:10.1021/nn403215e · Cited by 51
Yardley, D. A., Ward, P. J., Daniel, B. R., Eakle, J. F., Lamar, R. E., Lane, C. M., & Hainsworth, J. D. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.05.006 · Cited by 52
Mazor, R., King, E. M., Onda, M., Cuburu, N., Addissie, S., Crown, D., Liu, X.-F., Kishimoto, T. K., & Pastan, I. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717063115 · Cited by 49
‘Doc, will I ever eat steak again?’: diagnosis and management of alpha-gal syndrome
Patel, C., & Iweala, O. I. (2020) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000955 · Cited by 43
Risk-Based Control Strategies of Recombinant Monoclonal Antibody Charge Variants
Beck, A., Nowak, C., Meshulam, D., Reynolds, K., Chen, D. J., Pacardo, D. B., Nicholls, S. B., Carven, G. J., Gu, Z., Fang, J., et al. (2022) · Antibodies · doi:10.3390/antib11040073 · Cited by 51
Metadata
- Authors
- Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., Slebos, R. J., Zhou, Q., Gold, D., Hatley, T., Hicklin, D. J., & Platts-Mills, T. A. E.
- Affiliations
- Vanderbilt University (US)
- Bristol-Myers Squibb (United States) (US)
- Stanford University (US)
- Duke Medical Center (US)
- University of Virginia (US)
- Harvard University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-03-13
- Volume
- 358
- Issue
- 11
- Pages
- 1109-1117
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2361129
- OpenAlex
- W2140035322
- Cited by
- 1,521
- References
- 35
- Citations by year
- 2026: 63 · 2025: 79 · 2024: 64 · 2023: 83 · 2022: 78 · 2021: 78 · 2020: 94 · 2019: 80 · 2018: 78 · 2017: 109 · 2016: 90 · 2015: 99 · 2014: 88 · 2013: 97 · 2012: 94
- FWCI
- 57.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Damon Runyon Cancer Research Foundation
- Bristol-Myers Squibb
- Vanderbilt University
- Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation
- National Institutes of Health (20565, 2r01ai020565-29, 5r01ca118582-05, AI-20565)
- U.S. Public Health Service (AI-AADCRC-U19-070364)
- National Cancer Institute (R01-CA-118582, P50CA095103, P50CA95103)
- National Institute of Allergy and Infectious Diseases (AI 20565, R01AI035796, R01AI-020565, AI/EHS-35796, R29AI035796, R37AI020565)
- National Institute of Dental and Craniofacial Research (R01DE017982)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Keywords
- cetuximab, anaphylaxis, drug hypersensitivity, IgE antibodies, galactose-alpha-1,3-galactose, Fab fragment, monoclonal antibodies, epidermal growth factor receptor, pre-existing antibodies, colorectal cancer, head and neck squamous cell carcinoma
- MeSH terms
- Cetuximab, Adult, Aged, Aged, 80 and over, Anaphylaxis, Antibodies, Monoclonal, Epitopes, Antineoplastic Agents, Cross Reactions, Disaccharides, Female, Humans, Immunoglobulin E, Male, Middle Aged, Protein Binding, Protein Conformation, Case-Control Studies, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.